Eribulin - Eisai Co Ltd

Drug Profile

Eribulin - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Eribulin mesylate; Halaven; NSC-707389

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd; Harvard University
  • Developer Asan Medical Center; Eisai Co Ltd; Emory University; Merck & Co; National Cancer Institute (USA); PIQUR Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase I/II Bladder cancer; Solid tumours
  • Phase I Cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 08 Dec 2017 Additional efficacy data from the phase Ib/II ENHANCE-1 trial in Breast cancer presented at the San Antonio Breast Cancer Symposium 2017 (SABCS-2017)
  • 29 Nov 2017 China FDA accepts NDA for Eribulin for Breast cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) for review
  • 29 Nov 2017 Eisai Co Ltd re-submits NDA for Breast cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top